Reduction in Invasive Pneumococcal Disease Following Implementation of the Conjugate Vaccine in the Oxfordshire Region, England.

10:26 EDT 4th September 2015 | BioPortfolio

Summary of "Reduction in Invasive Pneumococcal Disease Following Implementation of the Conjugate Vaccine in the Oxfordshire Region, England."

Pneumococcal conjugate vaccine to 7 capsular types has been highly effective in the US since its introduction in 2000. The same vaccine was adopted by the UK in 2006. Ongoing surveillance since 1995 of invasive pneumococcal disease in Oxfordshire, UK, allowed assessment of the impact of vaccine intervention. The vaccine significantly reduced invasive pneumococcal disease among the target group, children less than 2 years; incidence rate ratio (IRR)=0.62 [95%CI 0.43-0.90] (p=0.008) comparing the 3 years pre- and post-implementation with a residual incidence of 22.4/100,000 children. The reduction was even greater when comparing 11 years pre with the 3 years post implementation of vaccine; IRR=0.53 [0.39- 0.70] p<0.0001. There was a marked direct effect of the vaccine evidenced by substantial reductions in the 7 serotypes contained in the vaccine. There was also a clear reduction in invasive pneumococcal disease for those serotypes contained in the vaccine among those older than 2 years when comparing both the 3 and 11 year pre PCV7 time periods with IRR=0.57 [0.47-0.69] p<0.0001 and IRR=0.50 [0.43-0.58] p<0.0001 respectively, indicating a strong herd effect. There was a significant, though moderate, rise in the serotypes not contained in the vaccine, with clear evidence for replacement in some serotypes.

Affiliation

1 University of Oxford;

Journal Details

This article was published in the following journal.

Name: Journal of medical microbiology
ISSN: 1473-5644
Pages:

Links

PubMed Articles [26024 Associated PubMed Articles listed on BioPortfolio]

Safety, Tolerability and Immunogenicity of 15-valent Pneumococcal Conjugate Vaccine in Toddlers Previously Vaccinated With 7-valent Pneumococcal Conjugate Vaccine.

Widespread use of 7-valent pneumococcal conjugate vaccine (PCV7) in children has led to significant reduction in pneumococcal disease in children and adults. However, diseases caused by serotypes not ...

The Czech Surveillance System for Invasive Pneumococcal Disease, 2008-2013: A Follow-Up Assessment and Sensitivity Estimation.

Invasive pneumococcal disease (IPD) is caused by Streptococcus pneumoniae and mostly presents as pneumonia, sepsis or meningitis. A notable portion of IPD cases is vaccine preventable and the pneumoco...

Differential Impact of Pneumococcal Conjugate Vaccines on Bacteremic Pneumonia Versus Other Invasive Pneumococcal Disease.

Bacteremic pneumonia (BP) accounts for ~35% of invasive pneumococcal disease (IPD) in young children. Our aims were to compare age, seasonal and serotype distribution of BP versus non-BP IPD and to de...

Pneumococcal Meningitis Vaccine Breakthroughs and Failures After Routine 7 and 13 Valent Pneumococcal Conjugate Vaccination in Children in France.

We collected cases of pneumococcal meningitis vaccine breakthrough (VBT) and vaccine failure (VF) from 2003 to 2013 after the implementation of pneumococcal conjugate vaccines (PCVs) in France. VBT ac...

Evaluating the implementation of the 13-valent pneumococcal vaccine supplementary dose program in Australian primary health care settings.

The availability of new pneumococcal conjugate vaccines covering a broader range of serotypes, has seen many countries introduce these into their national immunisation program. When transitioning from...

Clinical Trials [6580 Associated Clinical Trials listed on BioPortfolio]

Study Evaluating Immune Response of Children Revaccinated With Pneumococcal Conjugate Vaccine

The primary purpose of this study is to characterize the immune response to a single dose of 13-valent pneumococcal conjugate vaccine (13vPnC) in children previously vaccinated with a prim...

Effect of Two Versus Three Pneumococcal Conjugate Vaccinations

Two( 2) or three (3) instead of four vaccinations before the age of 6 months with pneumococcal conjugate vaccine are presumed to protect children against invasive pneumococcal disease like...

Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine Administered to Infants in Korea

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate va...

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

To assess whether HIV-infected infants who receive a heptavalent pneumococcal conjugate vaccine have more local reactions at the site of injection and systemic reactions than placebo subje...

Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomita...

Medical and Biotech [MESH] Definitions

A combined vaccine used to prevent infection with diphtheria and tetanus toxoid. This is used in place of DTP vaccine (DIPHTHERIA-TETANUS-PERTUSSIS VACCINE) when PERTUSSIS VACCINE is contraindicated.

A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)

A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.

An attenuated vaccine used to prevent and/or treat HERPES ZOSTER, a disease caused by HUMAN HERPESVIRUS 3.

A bacterial vaccine for the prevention of brucellosis in man and animal. Brucella abortus vaccine is used for the immunization of cattle, sheep, and goats.


Advertisement
 

Relevant Topic

Vaccine
Latest News Clinical Trials Research Drugs Reports Corporate
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Advertisement
 

Searches Linking to this Article